Another study showed that TOP2A was targeted for proteasomal degradation by histone deacetylase inhibitors by activating casein kinase 2α and GSK3β double phosphorylation, highlighting a novel potential mechanism of HCC treatment [29]. The gene discussed is TOP2A; the disease is hepatocellular carcinoma.